CN116270873A - Traditional Chinese medicine composition for treating dermatophyte infection - Google Patents
Traditional Chinese medicine composition for treating dermatophyte infection Download PDFInfo
- Publication number
- CN116270873A CN116270873A CN202310114781.6A CN202310114781A CN116270873A CN 116270873 A CN116270873 A CN 116270873A CN 202310114781 A CN202310114781 A CN 202310114781A CN 116270873 A CN116270873 A CN 116270873A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- parts
- medicine composition
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 208000007163 Dermatomycoses Diseases 0.000 title claims abstract description 23
- 239000000443 aerosol Substances 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 35
- 239000002994 raw material Substances 0.000 claims description 33
- 238000004821 distillation Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229940037003 alum Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 241001116389 Aloe Species 0.000 claims description 11
- 235000011399 aloe vera Nutrition 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 10
- 206010067197 Tinea manuum Diseases 0.000 description 9
- 201000004647 tinea pedis Diseases 0.000 description 9
- 244000045947 parasite Species 0.000 description 8
- 238000001256 steam distillation Methods 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 244000189123 Rumex japonicus Species 0.000 description 6
- 235000005247 Rumex japonicus Nutrition 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 5
- 244000294611 Punica granatum Species 0.000 description 5
- 235000014360 Punica granatum Nutrition 0.000 description 5
- 208000002474 Tinea Diseases 0.000 description 5
- 241000130764 Tinea Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 229960005040 miconazole nitrate Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000059168 Zanthoxylum ailanthoides Species 0.000 description 1
- 241000874379 Zanthoxylum molle Species 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating dermatophyte infection. The invention further provides a traditional Chinese medicine extract. The invention further provides a traditional Chinese medicine preparation. The invention further provides an aerosol and a preparation method thereof. The invention further provides application of the traditional Chinese medicine composition, the traditional Chinese medicine extract, the traditional Chinese medicine preparation or the aerosol in preparing medicines for treating dermatophyte infection. The traditional Chinese medicine composition for treating dermatophyte infection provided by the invention is used for treating dermatophyte infection, has the advantages of remarkable effect, high cure rate and no toxic or side effect, and is more easily accepted by patients.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine pharmacy, relates to a traditional Chinese medicine composition for treating dermatophyte infection, and in particular relates to a traditional Chinese medicine composition for treating dermatophyte infection, and preparation and application thereof.
Background
Dermatophytes (dermotophytes) are superficial fungi that are parasitic to the keratin tissue of the skin. Skin tinea (tinea) is the most common mycosis in world infection, and tinea manus and pedis are the most common. The external medicine for treating tinea manus, tinea pedis and dermatophyte infection on the market at present mainly takes cream and cream, but has very limited spray varieties with better relative absorption, and the research and development of antifungal aerosol with definite curative effect, mild medicine property, good absorption, small toxic and side effects and convenient carrying are urgently needed.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, the present invention aims to provide a traditional Chinese medicine composition for treating dermatophyte infection, which is used for solving the problem that the prior art lacks of a traditional Chinese medicine antifungal aerosol product which is convenient to carry, good in curative effect, good in compliance and safe.
To achieve the above and other related objects, the first aspect of the present invention provides a traditional Chinese medicine composition for treating dermatophyte infection, comprising the following raw material components:
20-40 parts of radix Rumicis Japonici;
5-15 parts of thunberg bark;
10-20 parts of pericarpium Granati;
1-10 parts of aloe;
10-20 parts of dried alum.
The second aspect of the invention provides a traditional Chinese medicine extract, which is obtained by adopting the traditional Chinese medicine composition as a raw material.
The third aspect of the invention provides a traditional Chinese medicine preparation, which comprises the traditional Chinese medicine composition provided by the first aspect of the invention and/or the traditional Chinese medicine extract provided by the second aspect of the invention in a therapeutically effective amount, and one or more conventional pharmaceutically acceptable auxiliary materials.
In a fourth aspect, the present invention provides a method of preparing an aerosol comprising: the components of the raw materials of the traditional Chinese medicine composition according to the first aspect of the invention are mixed according to the proportion, then water is added for soaking, the first aromatic liquid is collected after the first distillation, the second aromatic liquid is collected after the second distillation of the first aromatic liquid, and the aerosol is provided after the surfactant is added for full shaking, filtration and encapsulation.
In a fifth aspect the present invention provides an aerosol prepared by the method of the fourth aspect of the present invention.
A sixth aspect of the present invention provides the use of the Chinese medicinal composition provided in the first aspect of the present invention, the Chinese medicinal extract provided in the second aspect of the present invention, the Chinese medicinal preparation provided in the third aspect of the present invention, or the aerosol provided in the fifth aspect of the present invention in the preparation of a medicament for treating dermatophyte infection.
As described above, the traditional Chinese medicine composition for treating dermatophyte infection provided by the invention has the advantages that the preparation process is strictly carried out according to the asepsis operation design process flow, so that the effectiveness, safety and good stability of the medicament are ensured. The traditional Chinese medicine composition has reasonable compatibility of raw material medicines, definite action, no adverse reaction and no medicine dependence. The Chinese medicinal composition is convenient to carry and use after being prepared into aerosol. The traditional Chinese medicine composition can be used as a traditional Chinese medicine for treating dermatophyte infection, has good curative effect, good compliance, safety and high cure rate, is a pure traditional Chinese medicine preparation, has no toxic or side effect, and is more easily accepted by patients.
Drawings
Fig. 1 shows the results of fungal immunofluorescence detection of hyphae and spores not seen in patients of the observation group and the control group in example 7 of the present invention fig. 1A and 1B, wherein fig. 1A is the observation group and fig. 1B is the control group.
Fig. 2 shows the results of fungal immunofluorescence detection of hyphae and spores in patients of the observation group and the control group in example 7 of the present invention fig. 2A and 2B, wherein fig. 2A is the observation group and fig. 2B is the control group.
Detailed Description
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention. The test methods in the following examples, in which specific conditions are not noted, are generally conducted under conventional conditions or under conditions recommended by the respective manufacturers.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, materials used in the embodiments, any methods, devices, and materials of the prior art similar or equivalent to those described in the embodiments of the present invention may be used to practice the present invention according to the knowledge of one skilled in the art and the description of the present invention.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all employ techniques conventional in the art.
The first aspect of the invention provides a traditional Chinese medicine composition for treating dermatophyte infection, which comprises the following raw material components:
20-40 parts of radix Rumicis Japonici; specifically, 20-30 parts by weight, 30-40 parts by weight and 25-35 parts by weight;
5-15 parts of thunberg bark; specifically, 5-10 parts by weight, 10-15 parts by weight, and 7-13 parts by weight;
10-20 parts of pericarpium Granati; specifically, 10-15 parts by weight, 15-20 parts by weight and 12-18 parts by weight;
1-10 parts of aloe; specifically, 1-5 parts by weight, 5-10 parts by weight, and 2-8 parts by weight;
10-20 parts of dried alum; specifically, 10-15 parts by weight, 15-20 parts by weight and 12-18 parts by weight are mentioned.
In the present invention, the Rumex japonicus root (Radix Rumicis Japonici) is usually derived from the dry root of Rumex japonicus Houtt. The radix Rumicis Japonici has effects of cooling blood, stopping bleeding, killing parasite, and treating tinea.
In the present invention, the thunberg bark (Cortex Zanthoxyli Ailanthoidis) is usually derived from the bark of the plant stink-tree pricklyash Zanthoxylum ailanthoides Sieb.et Zucc. Or Zanthoxylum bungeanum Zanthoxylum molle red. The cortex Thunbergii has effects of dispelling pathogenic wind and dampness, and dredging channels and collaterals.
In the present invention, the pericarpium Granati (Punica granatum L) is usually derived from dried pericarp of Punica granatum l. The pericarpium Granati has effects of relieving diarrhea with astringents, stopping bleeding, and expelling parasites.
In the present invention, the Aloe Vera (Aloe Vera) is typically derived from a concentrated dried product of leaf juice of Aloe Vera l. The aloe has purgative, liver-fire removing and insecticidal effects.
In the present invention, the calcined alum (Alumen), also known as calcined alum, is typically derived from a mainly aqueous aluminum potassium sulfate (KAl (SO) 4 ) 2 ·12H 2 The calcined alum powder of O). The dried alum has the effects of eliminating phlegm, eliminating dampness, relieving diarrhea, stopping bleeding, removing toxic materials and killing parasites.
The raw material medicaments (or medicinal materials) of the raw material components adopted by the invention can be purchased from common medical shops or Chinese medicinal material selling companies, and the specification of the raw material medicaments accords with the national medical standard or the related regulations of Chinese pharmacopoeia and the like.
The traditional Chinese medicine composition for treating dermatophyte infection, which is compatible with the invention, fully follows the dialectical treatment principle of traditional Chinese medicine, and is invented especially for treating dermatophyte infection. The following Chinese medicines are mutually compatible, can exert the synergistic effect of the Chinese medicines, and the components of the raw materials of the Chinese medicines have the effects of interweaving, promoting and coordinating mutually. Specifically, the Rumex japonicus root in the prescription is a monarch drug and has the effects of clearing heat and detoxicating, cooling blood and stopping bleeding and killing parasites. Zhetong cortex, has effects of dispelling pathogenic wind, removing dampness, dredging collaterals, relieving pain, and promoting urination; the pericarpium Granati has the effects of astringing, stopping bleeding and expelling parasites; the two are ministerial drugs, and are used as ministerial drugs for eliminating dampness, killing parasites and relieving itching. Aloe is added for killing parasites and curing infantile malnutrition; dried alum is added, so that the Chinese herbal medicine is detoxified, insecticidal, dampness-eliminating and itching-relieving. The medicines are combined for use, so that the medicine has the functions of eliminating dampness, removing toxicity, killing parasites and relieving itching.
In a preferred embodiment of the present invention, the Chinese medicinal composition comprises the following raw material components:
27-32 parts of radix Rumicis Japonici;
8-12 parts of thunberg bark;
13-17 parts of pericarpium Granati;
3-7 parts of aloe;
13-17 parts of dried alum.
In a further preferred embodiment of the present invention, the Chinese medicinal composition comprises the following raw material components:
30 parts of radix Rumicis Japonici;
10 parts of thunberg bark;
15 parts of pericarpium Granati;
5 parts of aloe;
15 parts of dried alum.
The second aspect of the invention provides a traditional Chinese medicine extract, which is obtained by taking the traditional Chinese medicine composition of the first aspect of the invention as a raw material.
In a preferred embodiment of the present invention, the traditional Chinese medicine extract is obtained by extracting volatile components from the traditional Chinese medicine composition according to the first aspect of the present invention.
In a further preferred embodiment of the present invention, the method for extracting volatile components includes, but is not limited to, steam distillation, supercritical extraction, solvent extraction, evaporation extraction, etc., preferably steam distillation.
In a preferred embodiment of the present invention, the raw material components of the traditional Chinese medicine composition are crushed respectively and then mixed according to a proportion.
In a further preferred embodiment of the invention, the comminution is by grinding. The grinding method can uniformly mix the components so as to facilitate the extraction of the raw material components in the traditional Chinese medicine composition.
The third aspect of the invention provides a traditional Chinese medicine preparation, which comprises the traditional Chinese medicine composition provided by the first aspect of the invention and/or the traditional Chinese medicine extract provided by the second aspect of the invention in a therapeutically effective amount, and one or more conventional pharmaceutically acceptable auxiliary materials.
Pharmaceutically acceptable excipients include (but are not limited to): pharmaceutically acceptable carriers, diluents, fillers, binders, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives and other excipients. Therapeutically inert inorganic or organic carriers known to those skilled in the art include, but are not limited to, lactose, corn starch or derivatives thereof, talc, vegetable oils, waxes, fats, poly-antelope based compounds such as polyethylene glycols, water, sucrose, ethanol, glycerol and the like, various preservatives, lubricants, dispersants, flavoring agents. Humectants, antioxidants, sweeteners, colorants, stabilizers, salts, buffers and the like may also be added thereto as needed to aid stability of the formulation or to aid in enhancing activity or its bioavailability.
The pharmaceutical compositions of the present invention may also be used with other therapeutic agents.
The effective therapeutic dose of the pharmaceutical composition of the invention is based on the total weight of the raw materials, and the specific dose also considers the factors such as the administration route, the health condition of the patient and the like, which are all within the skill of the skilled doctor.
In a preferred embodiment of the present invention, the Chinese medicinal preparation includes, but is not limited to, tablets, injections, aerosols, pills, powders, granules, ointments, and the like. Specifically, the Chinese medicinal preparation is selected from one of tablets, injections, aerosols, pills, powders, granules or ointments. The above-mentioned Chinese medicinal preparations such as granules and pastes can be prepared by conventional methods.
In a fourth aspect, the present invention provides a method of preparing an aerosol comprising: the components of the raw materials of the traditional Chinese medicine composition according to the first aspect of the invention are mixed according to the proportion, then water is added for soaking, the first aromatic liquid is collected after the first distillation, the second aromatic liquid is collected after the second distillation of the first aromatic liquid, and the aerosol is provided after the surfactant is added for full shaking, filtration and encapsulation.
In a preferred embodiment of the present invention, the time for soaking in water is 3-5 hours; specifically, the time is 3-4h and 4-5h.
In a preferred embodiment of the present invention, the distillation reagent of the first distillation and the second distillation is water vapor.
In a preferred embodiment of the present invention, the ratio of the mass (g) of each raw material component added to the volume (mL) of the first aromatic liquid collected after distillation is 1:3-5, specifically, 1:3-4,1:4-5. Namely, the first aromatic liquid is 3-5 times of the raw material components of the traditional Chinese medicine composition; specifically, the amount is 3-4 times, and the amount is 4-5 times. Specifically, the volume of the first aromatic liquid collected after the distillation of 1g of the traditional Chinese medicine composition with water is 3-5mL, specifically 3-4mL and 4-5mL.
In a preferred embodiment of the present invention, the ratio of the mass (g) of each raw material component added to the volume (mL) of the second aromatic liquid collected after distillation is 1:1-2, such as 1:1-1.5,1:1.5-2. Namely, the second aromatic liquid is 1-2 times of the raw material components of the traditional Chinese medicine composition; specifically, the amount is 1-1.5 times, and 1.5-2 times. Specifically, the volume of the second aromatic liquid collected after the distillation of 1g of the traditional Chinese medicine composition with water is 1-2mL, specifically 1-1.5mL and 1.5-2mL.
The first aromatic liquid and the second aromatic liquid are aromatic water.
In a preferred embodiment of the present invention, the surfactant is tween 80.
In a preferred embodiment of the invention, the mass ratio of the surfactant to the raw material components of the traditional Chinese medicine composition is 1-2:20.
In a preferred embodiment of the invention, the filtration is a conventionally used filtration means.
In a preferred embodiment of the invention, the potting is a conventionally used aerosol filling process.
In a fifth aspect the present invention provides an aerosol prepared by the method of the fourth aspect of the present invention.
A sixth aspect of the present invention provides the use of the Chinese medicinal composition provided in the first aspect of the present invention, the Chinese medicinal extract provided in the second aspect of the present invention, the Chinese medicinal preparation provided in the third aspect of the present invention, or the aerosol provided in the fifth aspect of the present invention in the preparation of a medicament for treating dermatophyte infection.
In a preferred embodiment of the present invention, the tinea is various kinds of tinea, particularly tinea manus or tinea pedis.
The invention is further illustrated below in connection with specific examples, which are to be understood as being illustrative of the invention and not limiting the scope of the invention.
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Example 1
The traditional Chinese medicine composition for treating dermatophyte infection comprises the following raw material components in parts by weight: 30 parts of Rumex japonicus root, 10 parts of thunberg tree bark, 15 parts of pomegranate rind, 5 parts of aloe and 15 parts of dried alum. The above raw material components are respectively ground and crushed, and then mixed according to the above proportion, so as to obtain a traditional Chinese medicine composition sample 1.
Example 2
The traditional Chinese medicine composition for treating dermatophyte infection comprises the following raw material components in parts by weight: 27 parts of Rumex japonicus root, 12 parts of thunberg tree bark, 13 parts of pomegranate rind, 7 parts of aloe and 13 parts of dried alum. The above raw material components are respectively ground and crushed and then mixed according to the proportion, so that a traditional Chinese medicine composition sample 2 is obtained.
Example 3
The traditional Chinese medicine composition for treating dermatophyte infection comprises the following raw material components in parts by weight: 32 parts of Rumex japonicus root, 8 parts of thunberg tree bark, 17 parts of pomegranate rind, 3 parts of aloe and 17 parts of dried alum. The above raw material components are respectively ground and crushed, and then mixed according to the above proportion, so as to obtain a traditional Chinese medicine composition sample 3.
Example 4
50g of the traditional Chinese medicine composition sample 1 prepared in the embodiment 1 is soaked in water for 4 hours, the first steam distillation is carried out, then the first aromatic liquid is collected, the first aromatic liquid is 4 times of the traditional Chinese medicine composition sample 1, the second steam distillation is carried out on the first aromatic liquid, then the second aromatic liquid is collected, the second aromatic liquid is 1.5 times of the traditional Chinese medicine composition sample 1, then 3.75g of Tween 80 is added, and the traditional Chinese medicine composition sample 1 is fully shaken to clarify, filtered and encapsulated, so that the aerosol 1 is obtained.
Example 5
50g of the traditional Chinese medicine composition sample 2 prepared in the example 2 is soaked in water for 3.5 hours, the first steam distillation is carried out, then the first aromatic liquid is collected, the first aromatic liquid is 3.5 times of the traditional Chinese medicine composition sample 2, the second steam distillation is carried out on the first aromatic liquid, then the second aromatic liquid is collected, the second aromatic liquid is 1 time of the traditional Chinese medicine composition sample 2, then 2.5g of Tween 80 is added, and the mixture is fully shaken to clarify, filtered and encapsulated, so that aerosol 2 is obtained.
Example 6
50g of the traditional Chinese medicine composition sample 3 prepared in the embodiment 3 is soaked in water for 4.5 hours, the first steam distillation is carried out, then the first aromatic liquid is collected, the collected first aromatic liquid is 4.5 times of the traditional Chinese medicine composition sample 3, the second steam distillation is carried out on the first aromatic liquid, then the second aromatic liquid is collected, the collected second aromatic liquid is 2 times of the traditional Chinese medicine composition sample 3, then 5g of Tween 80 is added, and the mixture is fully shaken to clarify, filtered and encapsulated, so that aerosol 3 is obtained.
Example 7
In order to verify the effect of treating dermatophyte infection in the present invention, the present invention conducted the following clinical experiments.
1. Patient selection
The patients were selected for clinical trials, 400 cases of tinea manus patients were randomly extracted, namely, patients with dermatological department clinic harvest and treatment in seventh people hospitals between 1 month in 2020 and 6 months in 2021, and the patients were divided into 200 cases of observation group and control group. Experimental group 107 men and 93 women; age 29-56 years, average (32.56+ -5.27) years; 106 men and 94 women in the control group; ages 27-55, average (31.26 + -5.67) years. The comparison of the differences between the two groups of baseline data is not statistically significant (P > 0.05), and is comparable.
2. Diagnostic criteria
Inclusion criteria: (1) the clinical diagnosis of Fu Geshou tinea pedis diagnosis standard shows that dermatophytes are positive according to the detection result of fungal immunofluorescence; (2) no other oral, topical antifungal agents were used prior to observation.
Exclusion criteria: (1) gestational lactation patients; (2) immunosuppressant patients are used recently; (3) allergic patients to the used Chinese and western medicine components; (4) a diabetic patient; (5) is combined with skin damage or other skin diseases.
Diagnosis of traditional Chinese medicine: (1) blood dryness, wind generation and skin malnutrition (pale red tongue with little coating and deep and thready pulse); (2) the excessive interior heat and toxic pathogen (red tongue with yellow and greasy coating, wiry and slippery pulse, visible blisters and yellowish bleb liquid with visible erosion, maceration and exudation) are also the symptoms.
Western diagnosis: the result of the immunofluorescence detection of the fungus indicates that the fungus is positive.
3. Therapeutic method
The observation group and the control group were each applied with 2% miconazole nitrate cream (manufactured by cisapride pharmaceutical Co., ltd.) to the affected part, and gently rubbed to the skin for absorption twice a day, and the drug was stopped after two weeks of treatment.
The observation group was simultaneously added with the traditional Chinese medicine composition sample 1 prepared in the example 1, and the observation group was washed outside the affected part, namely, the affected part was washed 1 time a day after soaking in boiling water and cooling, and the medicine was stopped after 2 weeks of washing.
4. Curative effect
(1) Clinical efficacy criterion
And (3) healing: the tinea manus and pedis subsides, the fungal immunofluorescence detection result shows that the symptoms such as negative, itching feeling and erythema, scales and herpes churian are eliminated.
The effect is shown: the resolution area of tinea manus and pedis is more than or equal to 60%, the detection result of fungus immunofluorescence indicates negative, the itching feeling is obviously relieved, and the symptoms such as erythema, scales, herpes chuup and the like are obviously improved.
The method is effective: the resolution area of tinea manus and pedis is more than or equal to 20% and less than 60%, and the fungal immunofluorescence detection result indicates that the tinea manus and pedis is negative or positive, and the itch feel and clinical symptoms are relieved.
Invalidation: the resolution area of tinea manus and pedis rash is less than 20%, the result of the fungal immunofluorescence detection shows that the itching feeling of the affected part is not improved, and the clinical symptoms or physical signs are not improved or aggravated.
(2) Mycological efficacy evaluation
Mycological efficacy evaluation adopts mycoimmunofluorescence detection and is evaluated according to a second-level standard of elimination and non-elimination.
Clearing, namely, detecting the fungus immunofluorescence to be negative, and not finding hypha and spores; and the fungus immunofluorescence detection result is positive, and hyphae and spores are visible. Mycological clearance = number of clearance cases/total number of cases x 100%.
The data processing was performed by SPSS19.0 in the above (1) and (2), the measurement data were represented by (x.+ -.s), the t-test was performed, the count data were represented by (%), the χ2 test was performed, and the difference of P < 0.05 was statistically significant.
5. Statistics of treatment outcome
The comparison statistics of the clinical efficacy results when the observation group and the control group stop taking medicines are shown in the following table 1. The results of the treatment effect after 1 week of withdrawal for both groups are compared and counted in Table 2 below. The patients in the observation group and the control group did not see hyphae and spores, which are shown in fig. 1A and 1B, and the patients in the observation group and the control group did see hyphae and spores, which are shown in fig. 2A and 2B.
As can be seen from Table 1, the total effective rate of the observed group and the control group after treatment is 86.00% higher than the total effective rate of 69.50% of the control group treated with 2% miconazole nitrate cream alone. In terms of mycological curative effect, the observed group clearance rate is 46.00%, which is obviously higher than that of a control group treated by 2% miconazole nitrate emulsifiable paste for external use by 41.00%.
As can be seen from table 2, the total effective rate of the observation group and the control group is 95.00% in clinical efficacy after 1 week of discontinuation of the treatment of the patients in the observation group and the control group, which is significantly higher than 74.00% of the total effective rate of the control group treated with 2% miconazole nitrate cream alone for external use. The observed group clearance rate is 75.00% in mycological curative effect, which is obviously higher than 68.00% of the control group treated by 2% miconazole nitrate cream alone.
Table 1 comparison of results of therapeutic effects in two groups of withdrawal
Table 2 comparison of results of treatment effect after 1 week of two groups of withdrawal
While the invention has been described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various modifications and additions may be made without departing from the scope of the invention. Equivalent embodiments of the present invention will be apparent to those skilled in the art having the benefit of the teachings disclosed herein, when considered in the light of the foregoing disclosure, and without departing from the spirit and scope of the invention; meanwhile, any equivalent changes, modifications and evolution of the above embodiments according to the essential technology of the present invention still fall within the scope of the technical solution of the present invention.
Claims (10)
1. A Chinese medicinal composition comprises the following raw materials:
20-40 parts of radix Rumicis Japonici;
5-15 parts of thunberg bark;
10-20 parts of pericarpium Granati;
1-10 parts of aloe;
10-20 parts of dried alum.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material components in parts by weight: 27-32 parts of radix Rumicis Japonici;
8-12 parts of thunberg bark;
13-17 parts of pericarpium Granati;
3-7 parts of aloe;
13-17 parts of dried alum.
3. A Chinese medicinal extract obtained by extracting the Chinese medicinal composition according to claim 1 or 2.
4. The Chinese medicinal extract according to claim 3, wherein the Chinese medicinal extract is obtained by extracting volatile components from the Chinese medicinal composition according to claim 1 or 2.
5. A Chinese medicinal preparation comprising a therapeutically effective amount of the Chinese medicinal composition of any one of claims 1-2 and/or the Chinese medicinal extract of any one of claims 3-4, and one or more conventional pharmaceutically acceptable excipients.
6. The traditional Chinese medicine preparation according to claim 5, wherein the traditional Chinese medicine preparation is selected from one of a tablet, an injection, an aerosol, a pill, a powder, a granule or a paste.
7. A method of preparing an aerosol comprising: mixing the raw material components of the traditional Chinese medicine composition according to any one of claims 1-2 according to a proportion, adding water for soaking, distilling for the first time, collecting the first aromatic liquid, distilling the first aromatic liquid for the second time, collecting the second aromatic liquid, adding a surfactant, shaking sufficiently, filtering, and encapsulating to provide the aerosol.
8. A method of preparing an aerosol formulation according to claim 7, comprising any one or more of the following conditions:
1) The soaking time of the water is 3-5 hours;
2) The distillation reagent of the first distillation and the second distillation is water vapor;
3) The ratio of the added mass of the raw material components of the traditional Chinese medicine composition to the volume of the first aromatic liquid collected after distillation is 1:3-5, g/mL;
4) The ratio of the added mass of the raw material components of the traditional Chinese medicine composition to the volume of the second aromatic liquid collected after distillation is 1:1-2, g/mL;
5) The surfactant is Tween 80;
6) The mass ratio of the surfactant to the raw material components of the traditional Chinese medicine composition is 1-2:20.
9. An aerosol prepared by the method of any one of claims 7-8.
10. Use of a traditional Chinese medicine composition according to any one of claims 1-2, a traditional Chinese medicine extract according to any one of claims 3-4, a traditional Chinese medicine preparation according to any one of claims 5-6, or an aerosol according to claim 9 in the manufacture of a medicament for the treatment of dermatophyte infections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310114781.6A CN116270873B (en) | 2023-02-15 | 2023-02-15 | Traditional Chinese medicine composition for treating dermatophyte infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310114781.6A CN116270873B (en) | 2023-02-15 | 2023-02-15 | Traditional Chinese medicine composition for treating dermatophyte infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116270873A true CN116270873A (en) | 2023-06-23 |
| CN116270873B CN116270873B (en) | 2024-02-13 |
Family
ID=86793194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310114781.6A Active CN116270873B (en) | 2023-02-15 | 2023-02-15 | Traditional Chinese medicine composition for treating dermatophyte infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116270873B (en) |
-
2023
- 2023-02-15 CN CN202310114781.6A patent/CN116270873B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 杨卫平: "《临床常用中药手册》", vol. 1, 贵州科技出版社, pages: 1013 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116270873B (en) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069490B2 (en) | Yuricoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| US7357950B2 (en) | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders | |
| US20090004301A1 (en) | Method of treating dyshidrosis(pompholyx) and related dry skin disorders | |
| CN105362340B (en) | A kind of pharmaceutical composition for treating leukaemia and preparation method thereof | |
| CN108938759B (en) | Medicine or daily chemical product composition for treating hand-foot syndrome and preparation method and application thereof | |
| JP2003040787A (en) | Composition having physiological activity and method for producing the same | |
| CN110960624A (en) | Anti-fatigue composition and preparation method thereof | |
| Brendler et al. | Devil’s Claw (Harpagophytum procumbens DC) an evidence-based systematic review by the natural standard research collaboration | |
| US20060057237A1 (en) | Extract with anti-tumor and anti-poisonous activity | |
| CN116270873B (en) | Traditional Chinese medicine composition for treating dermatophyte infection | |
| CN105267867B (en) | Application of traditional Chinese medicine composition in preparation of medicine for eliminating cardiotoxic side effects of adriamycin | |
| CN1401365A (en) | Chinese health medicine | |
| Zakaria et al. | Evaluation of topical pomegranate extracts in management of oral Lichen Planus: A randomized clinical trial | |
| CN102552544A (en) | Externally-used Chinese herba preparation for treating neurodermatitis and preparation method of same | |
| Sharma | Triphala powder: A wonder of Ayurveda | |
| CN111437300A (en) | Traditional Chinese medicine composition for clearing heat, drying dampness, dispelling wind and relieving itching and preparation method thereof | |
| Panda | Aloe vera handbook cultivation, research finding, products, formulations, extraction & processing | |
| CN106604738B (en) | Pharmaceutical composition containing Massa Medicata Fermentata extract for wound treatment | |
| US20020006446A1 (en) | Botanical combinations for treating AIDS and immune-deficient patients to maintain good health and the process for preparing the same | |
| WO2013008249A2 (en) | Cell regenerating antioxidant | |
| KR20050083116A (en) | Antifungal composition | |
| Ravash et al. | The effect of hydroalcoholic extracts from Taraxacum officinale on blood indicators of kidney and liver functions in male rats | |
| CN105031033A (en) | Food or healthcare product or medicine composition containing lycium barbarum leaves | |
| CN1709496A (en) | Honey agaric extract and its preparing method | |
| JPH07188043A (en) | Relieving agent of pain caused by zoster virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |